Nisa Investment Advisors LLC grew its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 21.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 107,472 shares of the medical instruments supplier’s stock after buying an additional 18,638 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Becton Dickinson and were worth $23,004,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BDX. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the period. Harfst & Associates Inc. lifted its stake in Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the period. Harvest Fund Management Co. Ltd lifted its stake in Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after acquiring an additional 338 shares during the period. Acrospire Investment Management LLC lifted its stake in Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after acquiring an additional 600 shares during the period. Finally, Valeo Financial Advisors LLC purchased a new stake in Becton Dickinson and in the third quarter worth $191,000. 75.53% of the stock is owned by hedge funds and other institutional investors.

Becton Dickinson and Co (NYSE BDX) traded up $1.26 on Friday, reaching $225.82. The company’s stock had a trading volume of 1,554,900 shares, compared to its average volume of 1,643,650. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The company has a market capitalization of $52,060.00, a P/E ratio of 48.56, a price-to-earnings-growth ratio of 1.70 and a beta of 1.07. Becton Dickinson and Co has a twelve month low of $169.19 and a twelve month high of $229.68.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.12 earnings per share. sell-side analysts predict that Becton Dickinson and Co will post 10.89 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were issued a $0.75 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend was Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. Becton Dickinson and’s dividend payout ratio is 64.52%.

A number of analysts recently commented on BDX shares. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target for the company in a research note on Wednesday, January 3rd. Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. Argus raised their price target on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price target on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Morgan Stanley raised their price target on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Five research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $230.20.

ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/nisa-investment-advisors-llc-has-23-million-stake-in-becton-dickinson-and-co-bdx/1804677.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with Analyst Ratings Network's FREE daily email newsletter.